Intrexon | XON - Net Income

Stock Price
3.90
Daily Change
-0.08 -2.01%
Monthly
11.11%
Yearly
184.67%
Q2 Forecast
4.05

Intrexon reported $-20.32M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Agenus USD -10.63M 74.49M Dec/2025
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD -14.16M 30.98M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Thermo Fisher Scientific USD 1.96B 348M Dec/2025
Veracyte USD 41.15M 22.01M Dec/2025
Xencor USD -6.65M 626K Dec/2025